ClinicalTrials.gg
RecruitingNCT06710067Updated Dec 13, 2024

Urine Metabolites in the Diagnosis of Disease

An observational study in Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO) and Crohn Disease, sponsored by Luventix, Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Luventix, Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
72nd of 324
1,250 · median 221
Started
2024
with 123 others
Observational
325 of 2,339
69 open now
Primary completion
2025-09
later than 58 of 628 live
Registered
2,075th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 72nd largest by planned enrollment of the 324 observational ones that give a count, is one of 124 that started in 2024, is one of 325 observational ones, reaches primary completion later than 58 of the 628 other live ones, and was the 2,075th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.

This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.

The main questions it aims to answer are:

  1. Does the platform identify a disease signal within each disease cohort, compared to normal controls?
  2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?
03

Conditions studied

  • Colorectal Cancer
  • Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
  • Crohn Disease
  • Celiac Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants are recruited in the United States and/or internationally, with the following order of priority and preference: ·

  1. multi-center recruitment and eligibility screen at approximately 5-10 clinical sites, and/or
  2. clinical research organization (CRO) recruitment and eligibility screen, which may include internationally recruited patients and/or
  3. decentralized recruitment via social media sites directing to an online eligibility screen and/or
  4. Biobank/biorepository sourced frozen samples

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age at time of enrollment.
  • Able and willing to provide a one-time urine sample and comply with all study procedures for the study.
  • Able to understand the study procedures, able to provide consent to participate in the study, and willing to authorize release of relevant protected health information by consenting to a HIPAA medical release form.

Exclusion criteria

Exclusion Criteria:

  • Known to be pregnant.
  • A medical condition which, in the opinion of the Investigator and/or Sponsor, should preclude enrollment in the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Disease Cohort
06

What researchers measure

Primary outcomes

  1. Disease signal detection

    Disease signal detection quantification within each disease cohort, compared to normal controls.

    Time frame: From date of enrollment to the end of sample analysis, up to 100 weeks

  2. Test performance measures

    Sensitivity and specificity/false-positive rate

    Time frame: From date of enrollment to the end of sample analysis, up to 100 weeks

07

Study locations

4 of 4 sites recruiting
  • Unio Health Partners (Gastroenterology)
    Encinitas, California 92024, United States
    Recruiting
  • Digestive Health Associates
    Santa Monica, California 90404, United States
    Recruiting
    • La Juana, Study Coordinator · Contactelle20124me@gmail.com · 310-829-6789
    • Rahul Dixit, MD · Contact
  • Westside Gastro Care
    Santa Monica, California 90404, United States
    Recruiting
  • Bass Medical Group (Gastroenterology)
    Walnut Creek, California 94598, United States
    Recruiting
08

References and documents

Publications

  • Pasikanti KK, Ho PC, Chan EC. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Aug 15;871(2):202-11. doi: 10.1016/j.jchromb.2008.04.033. Epub 2008 Apr 29. PubMed 18479983 ↗
  • Dinges SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA, Cheng LL. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol. 2019 Jun;16(6):339-362. doi: 10.1038/s41585-019-0185-3. PubMed 31092915 ↗
  • Wittmann BM, Stirdivant SM, Mitchell MW, Wulff JE, McDunn JE, Li Z, Dennis-Barrie A, Neri BP, Milburn MV, Lotan Y, Wolfert RL. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 2014 Dec 26;9(12):e115870. doi: 10.1371/journal.pone.0115870. eCollection 2014. PubMed 25541698 ↗
  • Fan J, Hong J, Hu JD, Chen JL. Ion chromatography based urine amino Acid profiling applied for diagnosis of gastric cancer. Gastroenterol Res Pract. 2012;2012:474907. doi: 10.1155/2012/474907. Epub 2012 Jul 25. PubMed 22888338 ↗
  • Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, Kravstov A, Mullerad M. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol. 2008 Jun;179(6):2422-6. doi: 10.1016/j.juro.2008.01.084. Epub 2008 Apr 23. PubMed 18433783 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2025, 11 months after the start.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 11 months is below that.

Counting every sponsor, half of 646 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Nov 29, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2026
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710067
Lead sponsor
Luventix, Inc.
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Oct 1, 2024
Primary completion
Sep 2025 (estimated)
Completion
Sep 2026 (estimated)
Last update
Dec 13, 2024

Study contacts

Catherine Fine, MS, CGC
Contact
research@luventix.com
888-404-3143
John Spinosa, MD, PhD
principal investigator · Luventix, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion